# Capmatinib Hydrochloride (Tabrecta)

Source: https://ourhealthnetwork.com/drugs/capmatinib-hydrochloride
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Capmatinib Hydrochloride?

Capmatinib Hydrochloride (brand name: Tabrecta) is a kinase inhibitor. It is prescribed to treat carcinoma, non-small-cell lung.

## Brand names

Tabrecta

## Indications

Capmatinib Hydrochloride is prescribed for the treatment of carcinoma and non-small-cell lung.

## Conditions treated

- [Carcinoma](https://ourhealthnetwork.com/conditions/carcinoma)
- [Non-Small-Cell Lung](https://ourhealthnetwork.com/conditions/non-small-cell-lung)

## Mechanism of action

Capmatinib is a kinase inhibitor that targets MET, including the mutant variant produced by exon 14 skipping. MET exon 14 skipping results in a protein with a missing regulatory domain that reduces its negative regulation leading to increased downstream MET signaling.

## Drug classification

- Established Pharmacologic Class: kinase inhibitors
- Route of administration: ORAL

## Common side effects

and pneumonia, and vomiting, cough, decreased appetite, dyspnea, edema, fatigue, general physical health deterioration

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)